Translational research in regenerative medicine: A translational gap

Akifumi Matsuyama

研究成果: Article査読

抄録

A medical system is anticipated, where high-quality medical services are accessible without anxieties whenever we are ill. Innovative cell-based regenerative medical/medicinal products, and tissue-engineered medical products, have been used successfully to overcome certain life-threatening diseases, and there is still a need to design/produce more of these products. We translational researchers in regenerative medicine have been trying to translate our scientific findings from bench to bedside. Advanced therapies with cell-based regenerative medical/medicinal products constitute one of the most complex regulatory areas currently approached by clinical research and development in order to generate novel therapeutic applications for patients with incurable disease. We often lack the multidisciplinary skills needed to overcome intricate and complex regulatory tracks and might feel tired from pursuing clinical realization. Basic researchers and clinicians trying to translate stem cell biology into clinical practice might feel defeated by the endless regulatory requirements that apply. In order to help bridge this gap, in this chapter, we review practical issues that must be confronted in order to move from confidence in mechanism studies in animals into proof of concept studies in human. First, we briefly outline the basic definitions for cell products in the USA, EU and Japan, followed by a focused discussion of the pertinent actions of authorities in Japan.

本文言語English
ページ(範囲)163-172
ページ数10
ジャーナルPharmaceuticals Policy and Law
15
3-4
DOI
出版ステータスPublished - 01-12-2013
外部発表はい

All Science Journal Classification (ASJC) codes

  • 薬理学、毒性学および薬学(その他)
  • 健康政策

フィンガープリント

「Translational research in regenerative medicine: A translational gap」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル